期刊文献+

吡格列酮对缺血再灌注心肌细胞凋亡影响的实验研究 被引量:23

The effect of pioglitazone on apoptotic cardiomyocytes for ischemia reperfusion
原文传递
导出
摘要 目的观察吡格列酮对大鼠在体心肌缺血再灌注时心肌细胞凋亡的影响。方法实验动物随机分为2组,一为缺血30min再灌注30min组,进一步分为假手术组(n=5)、模型组(即溶剂对照组,n=6)和吡格列酮组(3mg/kg,n=7),测定心肌梗死面积;另一为缺血30min再灌注2h组,然后进一步分为假手术组(n=5)、模型组(n=6)及吡格列酮0·3mg/kg组(n=6)、1mg/kg组(n=7)和3mg/kg组(n=6),各用药组于缺血前30min静脉注射给药。然后,取心脏标本,石蜡包埋后切片,免疫组化检测凋亡蛋白Bax、Bcl-2、Caspase-3、PPARγ蛋白质表达,原位杂交方法检测PPARγmRNA表达。TUNEL法和DNA凝胶电泳观察心肌细胞凋亡。结果(1)与模型组比较,吡格列酮组梗死面积与缺血区面积之比减少28%(P<0·01),梗死面积与左室面积之比减少32%(P<0·01);(2)免疫组化和原位杂交结果示:吡格列酮0·3、1、3mg/kg可呈剂量依赖性减少Bax、Caspase-3,增加Bcl-2、PPARγ蛋白质以及PPARγmRNA表达;(3)TUNEL法检测吡格列酮可减少心肌细胞凋亡指数,3组作用均显著(P<0·05),但DNA凝胶电泳模型组、吡格列酮0·3、1mg/kg可见到DNA梯带,假手术组和吡格列酮3mg/kg则无DNA梯带。结论吡格列酮预处理可通过减少心肌细胞凋亡和梗死面积起到抗缺血再灌注损伤的作用。 Objective This study was to investigate the effect of pioglitazone on apoptotic cardiomyocytes with the model of ischemia-reperfusion at rat heart in vivo. Methods Sprague-Dawley rats were randomly divided into two groups. One was 30 min reperfusion group, which was subdivided into sham ( n = 5 ) , model ( vehicle, n = 6 ) and pioglitazone 3 mg/kg ( n = 7 ) with 30 min ischemia followed by 30 min reperfusion to detect the area of myocardial infarction (MI). Another was 2 h reperfusion group, which was further subdivided into sham (n = 5 ) , model (vehicle, n = 6 ) , and pioglitazone 0. 3 mg/kg (n = 6), 1 mg/kg (n = 7) and 3 mg/kg (n = 6). Apart from the sham, pioglitazone and vehicle were administered intravenously 30 min before occlusion. Then hearts were excised, paraffined and cut into 4μm thick. Immunohistochemistry, in situ hybridization, TUNEL and DNA agarose gel electrophoresis were performed to detect the expression of Bax, Bcl-2, Caspase-3 and PPARy protein and PPARy mRNA. Results (1) Compared with model, nec/aar of pioglitazone decreased by 28% ( P 〈 0. 01 ) . The nec/lv ratio reduced by 32% (P 〈 0. 01 ). (2)In a dose-dependent manner, the expressions of Bax and Caspase-3 were depressed, while the expression of Bcl-2, PPARy protein and PPARy mRNA were enhanced by pioglitazone. (3)The apoptotic index of subgroups injected pioglitazone reduced significantly by TUNEL compared with model ( P 〈 0. 05 ). Agarose gel electrophoresis demonstrated that DNA ladder existed in model, pioglitazone 0. 3 mg/kg and pioglitazone 1 mg/kg , but not pioglitazone 3 mg/kg. Conclusions Pioglitazone could protect the heart from I/R injury evidenced by the improvement in the expression of PPARy at the levels of protein and mRNA after pioglitazone administrated, and by the decrease in the apoptotic cardiomyocytes.
出处 《中华心血管病杂志》 CAS CSCD 北大核心 2005年第7期648-652,共5页 Chinese Journal of Cardiology
基金 国家自然科学基金资助项目(30270551) 全军"十五"计划面上课题资助项目(02M012)
  • 相关文献

参考文献19

  • 1潘军.脑缺血后细胞凋亡分子生物学机制的研究进展[J].医学综述,1998,4(10):537-540. 被引量:13
  • 2常连庆,谢晓华,陈雯,李朝晖,孙愚,刘珍荣,庞永正,唐朝枢.螺内酯抗钙调神经磷酸酶依赖的肾性高血压大鼠心肌肥厚作用机制[J].中华心血管病杂志,2004,32(3):254-257. 被引量:8
  • 3Aronson D, Rayfield EJ, Chesebro JH. Mechanisms determining course and outcome of diabetic patients who have had acute myocardial infarction. Ann Intern Med, 1997, 126:296-306.
  • 4Woodfield SL, Lundergan CF, Reiner JS,et al. Angiographic findings and outcome in diabetic patients treated with thrombolytic therapy for acute myocardial infarction: the GUSTO-I experience. J Am Coll Cardiol,1996, 28: 1661-1669.
  • 5Murry CE, Jennings RB, Reimer KA. Preconditioning with ischemia: a delay of lethal cell injury in ischemic myocardium. Circulation,1986, 74:1124-1136.
  • 6Chen L, Haugt WH, Yang B, et al. Preservation of endogenous antioxidant activity and inhibition lipid peroxidation as common mechanisms of antiatherosclerotic effects of vitamin E, lovastatin and amlodipioc. J AM Coll Cardiol, 1997, 30: 569-575.
  • 7Palojoki E, Saraste A, Eriksson A, et al. Cardiomyocyte apoptosis and ventricular remodeling after myocardial infarction in rats. Am J Physiol Heart Circ Physiol, 2001, 280:H2726-H2731.
  • 8Shiomi T, Tsutsui H,Hayashidani S, et al. Pioglitazone, a peroxisome proliferator-activated receptor-gamma agonist, attenuates left ventricular remodeling and failure after experimental myocardial infarction. Circulation, 2002,106: 3126-3132.
  • 9Thiemermann C, Zacharowski K. Selective activation of E-type prostanoid(3)-3 receptors reduces myocardial infarct size: a novel insight into the cardioprotective effects of prostaglandins. Pharmacol Ther, 2000,87:61-67.
  • 10林先和,李隆贵.过氧化物酶体增殖物激活受体γ基因转染对小鼠骨髓基质细胞向心肌细胞分化影响的研究[J].中华心血管病杂志,2004,32(7):622-625. 被引量:3

二级参考文献13

  • 1Fukuda K. Reprogramming of bone marrow mesenchymal stem cells into cardiomyocytes. C R Biol, 2002,325: 1027-1038.
  • 2Hunter JG,van Delft MF, Rachubinski RA, et al. Peroxisome proliferator-activated receptor gamma ligands differentially modulate muscle cell differentiation and MyoD gene expression via peroxisome proliferator-activated receptor gamma-dependent and -indepe
  • 3Czernik BL, Moerman EJ, Grant DF, et al. Divergent effects of selective peroxisome proliferator-activated receptor-γ2 ligands on adipocyte versus osteoblast differentiation. Endocrinology,2002,143:2376-2384.
  • 4Goodpaster BH, He J, Watkins S, et al. Skeletal muscle lipid content and insulin resistance: evidence for a paradox in endurance-trained athletes. J Clin Endocrinol Metab, 2001,86: 5755-5761.
  • 5Makino S, Fukuda K, Miyoshi S, et al. Cardiomyocytes can be generated from marrow stromal cells in vitro. J Clin Invest,1999,103:697-705.
  • 6Mueller E, Drori S, Aiyer A, et al. Genetic analysis of adipogenesis through peroxisome proliferator-activated receptor gamma isoforms. J Biol Chem,2002,277:41925-41930.
  • 7Poizat C, Sartorelli V, Chung G, et al. Proteasome-mediated degradation of the coactivator p300 impairs cardiac transcription. Mol Cell Biol, 2000, 20: 8643-8654.
  • 8Subbaramaiah K, Lin DT, Hart JC, et al. Peroxisome proliferator-activated receptor gamma ligands suppress the transcriptional activation of cyclooxygenase-2. Evidence for involvement of activator protein-1 and CREB-binding protein/p300. J Biol Chem, 2001,
  • 9Lehtinen SK, Rahkila P, Helenius M, et al. Down-regulation of transcription factors AP-1, Sp-1, and NF-kappa B precedes myocyte differentiation. Biochem Biophys Res Commun,1996, 229: 36-43.
  • 10Glover AB, Leyland-Jones B. Biochemistry of azacitidine: a review. Cancer Treat Rep, 1987, 71:959-964.

共引文献21

同被引文献212

引证文献23

二级引证文献68

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部